| Apolipoprotein E genotype and sex risk factors for Alzheimer disease: a meta-analysis SC Neu, J Pa, W Kukull, D Beekly, A Kuzma, P Gangadharan, LS Wang, ... JAMA neurology 74 (10), 1178-1189, 2017 | 538 | 2017 |
| QTdrugs list RL Woosley, CW Heise, KA Romero Available at: crediblemeds. org (Accessed 11 May 2018), 2017 | 205 | 2017 |
| Total kidney volume is a prognostic biomarker of renal function decline and progression to end-stage renal disease in patients with autosomal dominant polycystic kidney disease RD Perrone, MS Mouksassi, K Romero, FS Czerwiec, AB Chapman, ... Kidney international reports 2 (3), 442-450, 2017 | 122 | 2017 |
| Combining patient-level and summary-level data for Alzheimer’s disease modeling and simulation: a beta regression meta-analysis JA Rogers, D Polhamus, WR Gillespie, K Ito, K Romero, R Qiu, ... Journal of pharmacokinetics and pharmacodynamics 39, 479-498, 2012 | 103 | 2012 |
| A biological classification of Huntington's disease: the Integrated Staging System SJ Tabrizi, S Schobel, EC Gantman, A Mansbach, B Borowsky, ... The Lancet Neurology 21 (7), 632-644, 2022 | 94 | 2022 |
| CredibleMeds. org: what does it offer? RL Woosley, K Black, CW Heise, K Romero Trends in cardiovascular medicine 28 (2), 94-99, 2018 | 90 | 2018 |
| Nonclinical models for antituberculosis drug development: a landscape analysis T Gumbo, AJ Lenaerts, D Hanna, K Romero, E Nuermberger The Journal of infectious diseases 211 (suppl_3), S83-S95, 2015 | 89 | 2015 |
| Development of a multicompartment permeability‐limited lung PBPK model and its application in predicting pulmonary pharmacokinetics of antituberculosis drugs L Gaohua, J Wedagedera, BG Small, L Almond, K Romero, D Hermann, ... CPT: pharmacometrics & systems pharmacology 4 (10), 605-613, 2015 | 88 | 2015 |
| Forecasting accuracy of the hollow fiber model of tuberculosis for clinical therapeutic outcomes T Gumbo, JG Pasipanodya, K Romero, D Hanna, E Nuermberger Clinical Infectious Diseases 61 (suppl_1), S25-S31, 2015 | 85 | 2015 |
| The future is now: model‐based clinical trial design for Alzheimer's disease K Romero, K Ito, JA Rogers, D Polhamus, R Qiu, D Stephenson, R Mohs, ... Clinical Pharmacology & Therapeutics 97 (3), 210-214, 2015 | 78 | 2015 |
| Big data to smart data in Alzheimer's disease: The brain health modeling initiative to foster actionable knowledge H Geerts, PA Dacks, V Devanarayan, M Haas, ZS Khachaturian, ... Alzheimer's & Dementia 12 (9), 1014-1021, 2016 | 77 | 2016 |
| Safe drug use in long QT syndrome and Brugada syndrome: comparison of website statistics PG Postema, J Neville, JSSG de Jong, K Romero, AAM Wilde, ... Europace 15 (7), 1042-1049, 2013 | 71 | 2013 |
| Correlations between the hollow fiber model of tuberculosis and therapeutic events in tuberculosis patients: learn and confirm T Gumbo, JG Pasipanodya, E Nuermberger, K Romero, D Hanna Clinical Infectious Diseases 61 (suppl_1), S18-S24, 2015 | 68 | 2015 |
| Recommendations for the design of therapeutic trials for neonatal seizures JS Soul, R Pressler, M Allen, G Boylan, H Rabe, R Portman, P Hardy, ... Pediatric research 85 (7), 943-954, 2019 | 67 | 2019 |
| Systematic analysis of hollow fiber model of tuberculosis experiments JG Pasipanodya, E Nuermberger, K Romero, D Hanna, T Gumbo Clinical Infectious Diseases 61 (suppl_1), S10-S17, 2015 | 61 | 2015 |
| Biomarkers for drug development in early psychosis: current issues and promising directions DC Goff, K Romero, J Paul, MM Perez-Rodriguez, D Crandall, SG Potkin European Neuropsychopharmacology 26 (6), 923-937, 2016 | 60 | 2016 |
| Regulatory strategies for rare diseases under current global regulatory statutes: a discussion with stakeholders AE Mulberg, C Bucci-Rechtweg, J Giuliano, D Jacoby, FK Johnson, Q Liu, ... Orphanet Journal of Rare Diseases 14, 1-10, 2019 | 57 | 2019 |
| Understanding placebo responses in Alzheimer's disease clinical trials from the literature meta-data and CAMD database K Ito, B Corrigan, K Romero, R Anziano, J Neville, D Stephenson, ... Journal of Alzheimer's Disease 37 (1), 173-183, 2013 | 55 | 2013 |
| Warfarin interactions with substances listed in drug information compendia and in the FDA‐approved label for warfarin sodium M Anthony, K Romero, DC Malone, LE Hines, L Higgins, RL Woosley Clinical Pharmacology & Therapeutics 86 (4), 425-429, 2009 | 52 | 2009 |
| Adverse drug event causality analysis (ADECA): a process for evaluating evidence and assigning drugs to risk categories for sudden death RL Woosley, K Romero, CW Heise, T Gallo, J Tate, RD Woosley, S Ward Drug safety 40, 465-474, 2017 | 50 | 2017 |
